Clinical Data on Rhythm Control Strategies and Implications for Patient Care-Recent clinical data on rhythm control strategies and implications for patient care

Recent clinical data on rhythm control strategies and implications for patient care

Video Transcription

Video Summary

In this video, Paulus Gerjof discusses recent clinical data on rhythm control strategies for atrial fibrillation (AF). He highlights that even with optimal anticoagulation and background therapy, there is still a measurable rate of stroke, cardiovascular death, and heart failure hospitalizations in AF patients. The EAST-AF 412 trial tested whether early rhythm control therapy, incorporating antiarrhythmic drugs, could reduce these outcomes. The trial found that early rhythm control therapy reduced cardiovascular events by 21% over five years. The therapy was delivered mainly through antiarrhythmic drugs. The findings suggest that early rhythm control therapy should be considered the default strategy for most AF patients, especially the elderly and those with multiple comorbidities.

Keywords

rhythm control strategies

atrial fibrillation

clinical data

anticoagulation

cardiovascular events